Sonnet Biotherapeutics Holdings Inc SONN

Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed

[Jonathon Brown]

A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results. read article.

[PressRelease]

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411Watch the “What this Means” segment herePRINCETON, NJ, Nov. 12...read article.

[Iseneschal]

Now here is "The Bad News"..... and I will say it now.....All the Chsers & FOMO's have been had...... AGAIN ! Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten

[whytestocks]

NEWS: $SONN Sonnet BioTherapeutics Issued USTPO Patent Covering Two Novel Immunotherapeutic Drug Candidates2024-11-06 08:53:45 ET DENVER, Colo., Nov 06, 2024 ( 247marketnews.com )- Sonnet

[Iseneschal]

On watch  No position

[Iseneschal]

Yeeehaaaa

[Iseneschal]

  Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates   2024-11-06 05:30 ET - News Release

[whytestocks]

BREAKING NEWS: $SONN SONN announced stock split 1-82024-09-30 09:01:52 ET Sonnet BioTherapeutics Inc (SONN) announced stock split at a ratio of 1-for-8 on 2024-09-30 ... Full story available on

[whytestocks]

NEWS: $SONN Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitPRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the

[whytestocks]

Breaking News: $SONN Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell SeriesPRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the

[whytestocks]

JUST IN: $SONN Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateOngoing progress with both clinical trials of lead program, SON-1010, for

[MikeTester]

https://beyondspx.com/2024/08/02/sonnet-biotherapeutics-a-promising-oncology-focused-biotech-with-innovative-biologic-drugs/

[whytestocks]

Just In: $SONN Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross ProceedsPRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ

[whytestocks]

JUST IN: $SONN Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting | BenzingaPRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics

[PressRelease]

The SB101 and SB102 studies have together dosed 36 subjects to date as dose escalation continuesCytokine data show extended pharmacokinetics of SON-1010 with controlled induction of IFN? and no signs of cytokine release syndromeAll but one patient remain on study, with evidence of tumor...read article.

[PressRelease]

PRINCETON, NJ / ACCESSWIRE / November 1, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its SB101 clinical study with SON...read article.